Anirudh Gaur

Dr. Anirudh Gaur

Department of Physiology and Membrane Biology, University of California, Davis, Davis, California, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Sivanesan DakshanamurthySivanesan Dakshanamurthy
Sivanesan Dakshanamurthy
Anirudh GaurAnirudh Gaur
Anirudh Gaur
YCYou-Shin Chen
You-Shin Chen
HFHong-Bin Fang
Hong-Bin Fang
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAFWT and BRAFV600E. We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAFWT-NRASQ61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation. Reverse Phase Protein Array (RPPA) and immunoblot analyses show that both trametinib and MBZ inhibit the MAPK pathway, and cluster analysis revealed a protein cluster showing strong MBZ+trametinib - inhibited phosphorylation of MEK and ERK within 10 minutes, and its direct and indirect downstream targets related to stress response and translation, including ElK1 and RSKs within 30 minutes. Downstream ERK targets for cell cycle, including cMYC, were down-regulated, consistent with S- phase suppression by MBZ+trametinib, while apoptosis markers, including cleaved caspase-3, cleaved PARP and a sub-G1 population, were all increased with time. These data suggest that MBZ, a well-tolerated off-patent approved drug, should be considered as a therapeutic option in combination with trametinib, for patients with NRASQ61mut or other non-V600E BRAF mutant melanomas.

20 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ADAleksandra Dakic
Aleksandra Dakic
KDKyle DiVito
Kyle DiVito
SFShuang Fang
Shuang Fang
FSFrank Suprynowicz
Frank Suprynowicz
Anirudh GaurAnirudh Gaur
Anirudh Gaur
XLXuefeng Liu
Xuefeng Liu
ROCK inhibitor reduces Myc-induced apoptosis and mediates immortalization of human keratinocytes

16 July 2019 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Anirudh GaurAnirudh Gaur
Anirudh Gaur
HZHengbo Zhou
Hengbo Zhou
MAMaryam AbdusSamad
Maryam AbdusSamad
QQQing Qin
Qing Qin
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF inhibitor dabrafenib for BRAFV600 mutations. NRAS-mutated cell lines are also sensitive to MEK inhibitionin vitro, and NRAS-mutated tumors have also shown partial response to MEK inhibitors. However, melanoma still has high recurrence rates due to subpopulations, sometimes described as “melanoma initiating cells,” resistant to treatment. Since CD133 is a putative cancer stem cell marker for different cancers, associated with decreased survival, we examined resistance of patient-derived CD133(+) and CD133(-) melanoma cells to MAPK inhibitors. Human melanoma cells were exposed to increasing concentrations of trametinib and/or dabrafenib, either before or after separation into CD133(+) and CD133(-) subpopulations. In parental CD133-mixed lines, the percentages of CD133(+) cells increased significantly (p<0.05) after high-dose drug treatment. Presorted CD133(+) cells also exhibited significantly greater (p<0.05) IC50s for single and combination MAPKI treatment. siRNA knockdown revealed a causal relationship between CD133 and drug resistance. Microarray and qRT-PCR analyses revealed that ten of 18 ABC transporter genes were significantly (P<0.05) upregulated in the CD133(+) subpopulation, while inhibition of ABC activity increased sensitivity, suggesting a mechanism for increased drug resistance of CD133(+) cells.

13 April 2015 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Anirudh GaurAnirudh Gaur
Anirudh Gaur
VSVirginia A. Sanabria
Virginia A. Sanabria
LDLucia J. Dussan
Lucia J. Dussan
RSRahul Saxena
Rahul Saxena
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
While inorganic polyphosphate (polyP) promotes cell survival under conditions of environmental stress in bacterial cells, the roles of polyP in mammalian cells remain undefined. To investigate its involvement in survival and motility in human skin keratinocytes in response to environmental stresses such as UVB exposure or wounding, our studies focused on modulation of endogenous polyP levels by constitutive or inducible expression of ScPPX1, an S. cerevisiae exopolyphosphatase that degrades polyP, in the human keratinocyte HaCaT cell line. HaCaT cells were stably transfected with vectors expressing PPX1 constitutively, or following induction with tetracycline. RT-PCR, immunoblot and PPX1 enzymatic analysis, and intracellular polyP measurements confirmed expression of active PPX1 and reduction in endogenous polyP levels in derived clones. Cells depleted of polyP were exposed to UVB radiation or subjected to in vitro wounding assays. Dose-response and time course experiments revealed that reduction in polyP levels in HaCaT PPX1-expressing cells significantly sensitized these cells to UVB compared to control cells and attenuated the rate of wound healing in vitro, attributable at least in part to diminished cell proliferation and motility. Consistent with previous studies of bacteria lacking polyP, our results with human cells suggest that polyP may confer an enhanced ability to survive combined environmental stresses such as UVB irradiation and nutrient depletion and that these roles may be conserved between bacterial and animal kingdoms.

1 March 2021 in Metabolism
Verified
Journal Article
Closed access
Anirudh GaurAnirudh Gaur
Anirudh Gaur
ELElinor L. Lewis
Elinor L. Lewis
AHAnna C. Hergarden
Anna C. Hergarden
SSSarah E. Sheridan
Sarah E. Sheridan
LHLi He
Li He
JWJennifer L. Whistler
Jennifer L. Whistler

1 August 2015
Verified
Conference Paper
Closed access
MAMaryam AbdusSamad
Maryam AbdusSamad
Anirudh GaurAnirudh Gaur
Anirudh Gaur
HZHengbo Zhou
Hengbo Zhou
JZJohn L. Zapas
John L. Zapas
CSCynthia M. Simbulan-Rosenthal
Cynthia M. Simbulan-Rosenthal
DRDean S. Rosenthal
Dean S. Rosenthal
Melanoma is an aggressive and lethal form of cancer, responsible for 9,710 deaths in the US every year, as indicated by the Surveillance Epidemiology and End Results (SEER) program. Although early stages are surgically treatable, the advanced or metastatic stages are the most fatal, presumably due to resistance to chemotherapy, radiation or other therapies. Refractoriness of metastatic melanoma is due to self-renewal properties of a subpopulation of resistant cells, which may be the same as what have been termed “melanoma initiating cells” (MIC), many of which have been associated with the expression CD133. CD133 (PROM-1) is a 5-transmembrane-glycoprotein that is a cell surface marker for different cancers including late-stage cutaneous melanoma. By magnetic activated cell sorting, we isolated a CD133-positive population derived from a patient harboring a difficult-to-treat NRASQ61R/BRAFWT profile. The MIC were transfected with CD133-specific small-interfering RNA (siRNAs) to deplete CD133 protein levels in cells. Our results show that knocking down CD133 in NRASQ61R/BRAFWT mutant melanoma renders cells more sensitive to clinically employed-MEK/BRAF inhibitors. Thus, specific gene knockdown or small molecule targeting, along with the multikinase inhibitors, may be a high potency therapeutic of late-stage and recurrent melanoma. Analyses of patient-derived melanomas harboring different mutation signatures are currently in progress to determine if CD133 and MIC play broader roles in melanoma chemoresistance. Citation Format: Maryam AbdusSamad, Anirudh Gaur, Hengbo Zhou, John L. Zapas, Cynthia M. Simbulan-Rosenthal, Edward C. McCarron, Dean S. Rosenthal. CD133 knockdown sensitizes melanoma to kinase inhibitors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4224. doi:10.1158/1538-7445.AM2015-4224